Premium
Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent
Author(s) -
Dodds Melissa,
Hobday Patricia,
Schultz Brittney,
Maguiness Sheilagh
Publication year - 2018
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13442
Subject(s) - medicine , hydroxychloroquine , rituximab , prednisone , dermatology , lupus erythematosus , subacute cutaneous lupus erythematosus , systemic lupus erythematosus , belimumab , pediatrics , immunology , connective tissue disease , antibody , autoimmune disease , covid-19 , disease , b cell , b cell activating factor , infectious disease (medical specialty)
Subacute cutaneous lupus erythematosus is rare in children. Most patients respond well to conventional therapy with prednisone, hydroxychloroquine, or both. Other case reports and small series have reported successful clearance with rituximab in adults. We report an adolescent who obtained remission with rituximab after failing conventional therapy.